newsfilter
← Earnings
Earnings Releases·

Precigen — Third Quarter 2026 Earnings Summary

Precigen reported third-quarter 2026 net income of $35.8 million, driven by a 37% quarter-over-quarter increase in PAPZIMEOS net revenue to $72.9 million. The company achieved positive cash flow from operating activities of $11.9 million, reaching this milestone a full quarter ahead of its guidance. As of September 30, 2026, Precigen held $51.0 million in cash, cash equivalents, and investments while well over 500 patients had initiated PAPZIMEOS treatment. Additionally, the FDA granted Platform Technology Designation to the AdenoVerse platform, and new long-term data presented at AAO-HNSF 2026 showed durable complete responses up to five years post-treatment.

Company
PRECIGEN INC
Sector
Healthcare
Industry
Biotechnology